Absence of the del (exons 9–12) mutation in breast/ovarian cancer families outside of Mexican Hispanics

Diana Torres, Muhammad U. Rashid, Antje Seidel-Renkert, Jeffrey N. Weitzel, Ignacio Briceno, Ute Hamann

► To cite this version:

Diana Torres, Muhammad U. Rashid, Antje Seidel-Renkert, Jeffrey N. Weitzel, Ignacio Briceno, et al.. Absence of the del (exons 9–12) mutation in breast/ovarian cancer families outside of Mexican Hispanics. Breast Cancer Research and Treatment, 2009, 117 (3), pp.679-681. 10.1007/s10549-009-0383-4 . hal-00535354

HAL Id: hal-00535354

<https://hal.science/hal-00535354>

Submitted on 11 Nov 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Absence of the *BRCA1* del (exons 9–12) mutation in breast/ovarian cancer families outside of Mexican Hispanics

Diana Torres · Muhammad U. Rashid · Colombian Breast Cancer Study Group (COLBCS) ·
Antje Seidel-Renkert · Jeffrey N. Weitzel ·
Ignacio Briceno · Ute Hamann

Received: 17 March 2009 / Accepted: 17 March 2009 / Published online: 31 March 2009
© Springer Science+Business Media, LLC. 2009

Keywords *BRCA1* · Genomic rearrangements ·
Exon 9–12 deletion · Ethnic groups

To the editor

The frequency and spectrum of germ line mutations in the high-penetrance breast cancer susceptibility genes *BRCA1* and *BRCA2* shows considerable variation by ethnic group. Most genetic epidemiological studies of the *BRCA* genes have been performed among Caucasian populations [1],

Diana Torres and Muhammad U. Rashid contributed equally to this work.

Colombian Breast Cancer Study Group (COLBCS): Angela Beltran, Viviana Ariza, Angela Umana, MSc., Fabian Gil (Pontificia Universidad Javeriana, Bogota); clinicians and hospitals: Jose Fernando Robledo, M.D., Jose Caicedo, M.D., Elías Quintero, M.D., Alejandro Orozco, M.D. (Country Clinic, Bogota); Mauricio Tawil, M.D., Lilian Torregrosa, M.D. (Pontificia Universidad Javeriana, Bogota).

M. U. Rashid · A. Seidel-Renkert · U. Hamann (✉)
Deutsches Krebsforschungszentrum, Research Group Molecular
Genetics of Breast Cancer, Im Neuenheimer Feld 580, 69120
Heidelberg, Germany
e-mail: u.hamann@dkfz-heidelberg.de

D. Torres · I. Briceno
Instituto de Genetica Humana, Pontificia Universidad Javeriana,
Universidad de la Sabana, Bogota, Colombia

M. U. Rashid
Shaukat Khanum Memorial Cancer Hospital and Research
Centre, Lahore, Pakistan

J. N. Weitzel
Department of Clinical Cancer Genetics, City of Hope, Duarte,
CA, USA

with the exception of a few studies involving other ethnic groups, such as Hispanics [2–4], Asians [5, 6], and African Americans [7–9]. In most of these studies only the frequencies of sequence detectable *BRCA* mutations were reported and large genomic rearrangements including deletions and insertions of one or more exons, which account for 6–15% of all deleterious mutations in these genes have infrequently been considered [10–12].

Most *BRCA* mutations are unique; however, few recurrent mutations with founder effects have been found in European, Hispanic, American and Asian populations [13]. In a recent study on Hispanic high-risk breast/ovarian cancer families of mainly Mexican descent from South California, Weitzel and colleagues reported the identification of a novel deletion of *BRCA1* exons 9 through 12 using multiplex quantitative differential polymerase chain reaction (PCR) analysis. The deletion was detected in 3.8% of families negative for sequence detectable *BRCA* mutations [14]. The large genomic rearrangement mutation is considered deleterious as it results in loss of critical functional domains as well as premature truncation of the *BRCA1* protein. Given the relatively high prevalence of the deletion in this cohort, the authors suggest to include the screening for this mutation in the genetic testing strategy in Hispanic women without sequence detectable *BRCA* mutations.

The spectra of recurrent sequence detectable *BRCA* mutations, including some with founder effects in a cohort of Hispanic breast/ovarian cancer families of predominantly Mexican descent from the United States and in a cohort from Colombia have previously been shown to differ completely, with different common mutations being identified in the two populations [2, 4]. In order to investigate, whether the novel *BRCA1* founder deletion is also specific for Hispanic families of Mexican descent or whether it also occurs in other Hispanic cohorts, we screened 229 cancer

families from Colombia for its presence. Moreover, we assessed whether this mutation is present in families belonging to two other ethnic groups, including 255 Asian families from Pakistan and 54 Caucasian families from Germany. A description of the families under investigation is shown in Table 1. Among the Colombian, Pakistani and German families, 40, 146 and 54 families without sequence detectable *BRCA*-mutations, respectively, have been previously described [4, 5, 15–17]. The remaining families were newly recruited within an ongoing breast cancer case-control study in Colombia and a hereditary breast cancer study in Pakistan. All newly recruited families were

screened for the presence of the common *BRCA* mutations specific for each of these ethnic groups (three founder mutations in Colombia; three founder and one recurrent mutation in Pakistan) and none were detected (unpublished data). The research study was approved by the local Ethics committees. *BRCA1* del (exons 9–12) mutation analysis was performed using a 3-primer PCR assay as previously described [14]. PCR products, including both positive and negative control samples, were separated by size on 1.5% agarose gels and visualized by ethidium bromide staining. The fragment sizes were 1,145 bp for the wild type and 742 bp for the deletion mutation.

Table 1 Breast/ovarian cancer families from Colombia, Pakistan and Germany under investigation

Phenotype of families	No. of families	No. of <i>BRCA1</i> del (exons 9-12) carriers
<i>Hispanic breast/ovarian cancer families from Colombia</i>		
All families	229	0/229
Female breast cancer families (bilateral)		
1 case (1) diagnosed ≤ 35 years	4	
2 cases (9)	99	
3 cases (4)	68	
≥ 4 cases	28	
Male breast cancer families		
≥ 1 case (1)	1	
Breast-ovarian cancer families		
≥ 1 breast cancer and ≥ 1 ovarian cancer	27	
Ovarian cancer families		
≥ 2 cases	2	
<i>Asian breast/ovarian cancer families from Pakistan</i>		
All families	255	0/255
Female breast cancer families (bilateral)		
1 case (2) diagnosed ≤ 30 years	135	
1 case (10) diagnosed ≤ 50 years	10	
2 cases (1) with ≥ 1 diagnosed ≤ 50 years	31	
3 cases (2) with ≥ 1 diagnosed ≤ 50 years	18	
≥ 4 cases with ≥ 1 diagnosed ≤ 50 years	9	
Male breast cancer families		
≥ 1 case of male breast cancer	11	
Breast-ovarian cancer families		
≥ 1 breast cancer and ≥ 1 ovarian cancer	18	
Ovarian cancer families		
1 case diagnosed ≤ 45 years	21	
2 cases with ≤ 1 case diagnosed before 45 years	2	
<i>Caucasian breast/ovarian cancer families</i>		
All families	54	0/54
Female breast cancer families (bilateral)		
3 cases (3) with ≥ 1 diagnosed ≤ 50 years	19 ^a	
≥ 4 cases (6) with ≥ 1 diagnosed ≤ 50 years	24 ^b	
Breast-ovarian cancer families		
≥ 1 breast cancer and ≥ 1 ovarian cancer	11	

^a Including one family with a male breast cancer

^b Including two families with a male breast cancer

The present study included 538 affected individuals from breast and/or ovarian cancer families. The mean ages of female breast cancer onset in Colombian, Pakistani and German patients were 50 years (range 23–83, $n = 224$), 30 years (range 19–70, $n = 218$) and 44 years (range 24–70, $n = 54$), respectively. The mean age of ovarian cancer onset was 54 years (range 34–71, $n = 4$) for Colombian patients and 33 years (range 22–48, $n = 26$) for Pakistani patients.

None of the 538 analyzed samples carried the *BRCA1* del (exons 9–12) mutation (Table 1). This finding suggests that this mutation is not present or is present at an extremely low frequency in Hispanic families from Colombia as well as in Pakistani and German populations.

The absence of the *BRCA1* del (exons 9–12) mutation in Hispanic families from Colombia shows that this mutation does not contribute to hereditary breast/ovarian cancer in this population, nor in Pakistani and German populations. Our data confirm our previous finding that the spectra of the *BRCA* founder mutations differ between Hispanic families of Mexican origin from the United States and families from Colombia. These findings provide further evidence that specific risk assessment strategies for the different Hispanic populations in South America and in the United States need to be developed.

Acknowledgments We are indebted to all women who had participated in this study. We gratefully acknowledge support by the physicians in Pakistan and Germany. This work was financed by the Deutsches Krebsforschungszentrum, Heidelberg and in part by a grant of Dr. Weitzel from the California Breast Cancer Research Program.

References

1. Szabo CI, King MC (1997) Population genetics of *BRCA1* and *BRCA2*. *Am J Hum Genet* 60(5):1013–1020
2. Weitzel JN, Lagos V, Blazer KR, Nelson R, Ricker C, Herzog J, McGuire C, Neuhausen S (2005) Prevalence of *BRCA* mutations and founder effect in high-risk Hispanic families. *Cancer Epidemiol Biomarkers Prev* 14(7):1666–1671. doi:10.1158/1055-9965.EPI-05-0072
3. Jara L, Ampuero S, Santibanez E, Seccia L, Rodríguez J, Bustamante M, Martínez V, Catenaccio A, Lay-Son G, Blanco R, Reyes JM (2006) *BRCA1* and *BRCA2* mutations in a South American population. *Cancer Genet Cytogenet* 166(1):36–45. doi:10.1016/j.cancergencyto.2005.08.019
4. Torres D, Rashid MU, Gil F, Umana A, Ramelli G, Robledo JF, Tawil M, Torregrosa L, Briceno I, Hamann U (2007) High proportion of *BRCA1/2* founder mutations in Hispanic breast/ovarian cancer families from Colombia. *Breast Cancer Res Treat* 103(2):225–232. doi:10.1007/s10549-006-9370-1
5. Rashid MU, Zaidi A, Torres D, Sultan F, Benner A, Naqvi B, Shakoobi AR, Seidel-Renkert A, Farooq H, Narod S, Amin A, Hamann U (2006) Prevalence of *BRCA1* and *BRCA2* mutations in Pakistani breast and ovarian cancer patients. *Int J Cancer* 119(12):2832–2839. doi:10.1002/ijc.22269
6. Liede A, Narod SA (2002) Hereditary breast and ovarian cancer in Asia: genetic epidemiology of *BRCA1* and *BRCA2*. *Hum Mutat* 20(6):413–424. doi:10.1002/humu.10154
7. Hughes C, Gomez-Caminero A, Benkenndorf J, Kerner J, Isaacs C, Barter J, Lerman C (1997) Ethnic differences in knowledge and attitudes about *BRCA1* testing in women at increased risk. *Patient Educ Couns* 32(1–2):51–62. doi:10.1016/S0738-3991(97)00064-5
8. Hughes C, Lerman C, Lustbader E (1996) Ethnic differences in risk perception among women at increased risk for breast cancer. *Breast Cancer Res Treat* 40(1):25–35. doi:10.1007/BF01806000
9. Croyle RT, Lerman C (1999) Risk communication in genetic testing for cancer susceptibility. *J Natl Cancer Inst Monogr* 25:59–66
10. Gad S, Caux-Moncoutier V, Pages-Berhouet S, Gauthier-Villars M, Coupier I, Pujol P, Frénay M, Gilbert B, Maugard C, Bignon YJ, Chevrier A, Rossi A, Fricker JP, Nguyen TD, Demange L, Aurias A, Bensimon A, Stoppa-Lyonnet D (2002) Significant contribution of large *BRCA1* gene rearrangements in 120 French breast and ovarian cancer families. *Oncogene* 21(44):6841–6847. doi:10.1038/sj.onc.1205685
11. Casilli F, Tournier I, Sinilnikova OM, Coulet F, Soubrier F, Houdayer C, Hardouin A, Berthet P, Sobol H, Bourdon V, Muller D, Fricker JP, Capoulade-Metay C, Chompret A, Nogues C, Mazoyer S, Chappuis P, Maillat P, Philippe C, Lortholary A, Gesta P, Béziau S, Toulas C, Gladieff L, Maugard CM, Provencher DM, Dugast C, Delvincourt C, Nguyen TD, Faivre L, Bonadona V, Frébourg T, Lidereau R, Stoppa-Lyonnet D, Tosi M (2006) The contribution of germline rearrangements to the spectrum of *BRCA2* mutations. *J Med Genet* 43(9):e49. doi:10.1136/jmg.2005.040212
12. Palma MD, Domchek SM, Stopfer J, Erlichman J, Siegfried JD, Tigges-Cardwell J, Mason BA, Rebbeck TR, Nathanson KL (2008) The relative contribution of point mutations and genomic rearrangements in *BRCA1* and *BRCA2* in high-risk breast cancer families. *Cancer Res* 68(17):7006–7014. doi:10.1158/0008-5472.CAN-08-0599
13. Ferla R, Calo V, Cascio S, Badalamenti G, Carreca I, Surmacz E, Colucci G, Bazan V, Russo A (2007) Founder mutations in *BRCA1* and *BRCA2* genes. *Ann Oncol* 18(Suppl 6):vi93–vi98. doi:10.1093/annonc/mdm234
14. Weitzel JN, Lagos VI, Herzog JS, Judkins T, Hendrickson B, Ho JS, Ricker CN, Lowstuter KJ, Blazer KR, Tomlinson G, Scholl T (2007) Evidence for common ancestral origin of a recurring *BRCA1* genomic rearrangement identified in high-risk Hispanic families. *Cancer Epidemiol Biomarkers Prev* 16(8):1615–1620. doi:10.1158/1055-9965.EPI-07-0198
15. Hamann U, Brauch H, Garvin AM, Bastert G, Scott RJ (1997) German family study on hereditary breast and/or ovarian cancer: germline mutation analysis of the *BRCA1* gene. *Genes Chromosomes Cancer* 18(2):126–132. doi:10.1002/(SICI)1098-2264(199702)18:2<126::AID-GCC7>3.0.CO;2-4
16. Hamann U, Haner M, Stosiek U, Bastert G, Scott RJ (1997) Low frequency of *BRCA1* germline mutations in 45 German breast/ovarian cancer families. *J Med Genet* 34(11):884–888. doi:10.1136/jmg.34.11.884
17. Hamann U, Liu X, Lange S, Ulmer HU, Benner A, Scott RJ (2002) Contribution of *BRCA2* germline mutations to hereditary breast/ovarian cancer in Germany. *J Med Genet* 39(3):E12. doi:10.1136/jmg.39.3.e12